Table 3 Rectal carriage of (non-intrinsic) antibiotic resistant microorganisms
Patients, n/N (%) | |||
|---|---|---|---|
OAP | Placebo | P value | |
Baseline | |||
Number of valid rectal cultures | 35/39 (89.7) | 31/39 (79.5) | |
Rectal carriage of HRE | |||
ESBL-E | 2/35 (5.7) | 1/31 (3.2) | 1.000 |
Carbapenem-resistant Gram-negative bacteria | 1/35 (2.9) | 2/31 (6.5) | 0.597 |
Carbapenemase-gene present | 1/35 (2.9) | 2/31 (6.5) | 0.597 |
Tobramycin-resistant Gram-negative bacteria | 12/35 (34.3) | 14/31 (45.2) | 0.452 |
Acquired aminoglycoside resistance gene present | 1/35 (2.8) | 5/31 (16.1) | 0.088 |
Colistin-resistant Gram-negative bacteria | 7/35 (20.0) | 6/31 (19.4) | 1.000 |
Acquired colistin resistance gene present | 0/35 (0.0) | 0/31 (0/0) | 0 |
30 days after surgery | |||
Number of valid rectal cultures | 34/36 (94.4) | 28/35 (80.0) | |
Rectal carriage of HRE | |||
ESBL-E | 1/34 (2.9) | 1/28 (3.6) | 1.000 |
Carbapenem-resistant Gram-negative bacteria | 0/34 (0.0) | 1/28 (3.6) | 0.452 |
Carbapenemase gene present | 0/34 (0.0) | 1/28 (3.6) | 0.452 |
Tobramycin-resistant Gram-negative bacteria | 15/34 (44.1) | 10/28 (35.7) | 0.606 |
Acquired aminoglycoside resistance gene present | 7/34 (2.1) | 5/28 (17.9) | 0.318 |
Colistin-resistant Gram-negative bacteria | 4/34 (11.9) | 4/28 (14.3) | 0.320 |
Acquired colistin resistance gene present | 0/34 (0.0) | 0/28 (0.0) | 1.000 |